They did not recommend that additional cancer screening was required at this time.All medications cause side effects, most of which are mild-to-moderate and will go away with time. The FDA is not currently recommending that additional testing is needed but has stated that the risks of continuing to take the medication outweigh the benefits.Patients who took Belviq or Belviq XR and who were diagnosed with cancer may be considering filing lawsuits against Eisai to seek compensation for their injuries.Belviq (lorcaserin) is a medication used for chronic weight management. The Belviq lawsuit claims that the use of Belviq can increase the risk of cancer, especially colorectal, pancreatic, and lung cancer. Belviq was approved to be used as part of a weight management program which included reduced calorie diet and increased physical activity in adult patients with an initial body mass index (BMI) ofA normal BMI is considered to be 18.5 to 24.9 kg/ m².Belviq was approved by the U.S. Food and Drug Administration (FDA) in 2012 but long-term effects on cardiovascular health have been an ongoing concern in the diet drug field. Allegations Raised in Belviq Recall Lawsuits The lawyers at Saiontz & Kirk, P.A. Patients are cautioned about operating hazardous equipment or driving until they know how the medication will affect them.Psychiatric disorders – Symptoms of hallucinations, euphoria and dissociation were experienced by some taking Belviq. Prescribing information also recommends monitoring patients for suicidal thoughts and behaviors or worsening of depression and that medication should be discontinued if severe mood changes occur.The FDA has announced that Japanese drug maker Eisai Inc. agreed to withdraw diet drug Belviq and Belviq XR after the medication was linked to an increase risk of cancer including colorectal cancer, pancreatic cancer and lung cancer.Seeger Weiss is investigating Belviq-related cancer and potential harm that may have come from taking the weight control drug.People or loved ones of those who developed or were diagnosed with cancer after taking Belviq or Belviq XR may be eligible for compensation and should seek advice from legal experts.By submitting this form I agree to the terms of SeegerWeiss.com Since its establishment in 1999, Seeger Weiss has led some of the most complex and high-profile litigations in the U.S.With offices in New York, New Jersey and Philadelphia, our firm is primarily known for multidistrict mass torts and class actions in both state and federal courts, with a strong track record of landmark verdicts and settlements.NOTICE: This website, the related links, and the social media accounts of Seeger Weiss contain Attorney Advertising.
are reviewing potential lawsuits on behalf of former users of the drug who have since been diagnosed with Pancreatic cancer, Colorectal Cancer, Lung Cancer, or another cancer afflicting the digestive tract.Our Belviq attorneys are specialized in dangerous drugs and are currently reviewing potential Belviq lawsuits and Belviq class action lawsuits.The manufacturer of this weight loss drug has a moral and legal responsibility to research and present all of the potential risks. In 2012, Belviq was the first obesity drug to be approved in 13 years.However, even before the drug was introduced, there were concerns regarding the safety of the drug.Arena complies with the requirements of the FDA, and submitted a complete The trials’ purpose was to determine the amount of risk to cardiovascular health, since, in 1997, the similar weight-loss drugs fenfluramine and dexfenfluramine were withdrawn from the market after evidence emerged that these drugs caused heart valve damage, assumed to be related to activation of the serotonin 2B receptor on heart tissue.The trial concludes that with 10 milligrams doses, twice a day, Belviq does not appear to activate the serotonin 2B receptor.The trial results did not account for increased risk of cancer since the study was required in order to affirm cardiovascular health would not be affected.Belviq lawyers correctly acknowledge that users may have avoided cancer if the drug manufacturer had adequately researched the side effects of Belviq and warned about the risk of cancer, which should have been diligently researched in 2010 – especially after the FDA first rejected the new drug application for Belviq due to inadequate data to confirm the drug would not increase risk of cancer.Although the initial trial indicated the drug was safe to use, over the long-term, it found that more patients taking lorcaserin (462; 7.7 percent) were diagnosed with cancer compared to those taking a placebo, which is an inactive treatment (423; 7.1 percent).The most common types of cancers specifically linked with the drug are Pancreatic Cancer, Colorectal Cancer, and Lung Cancer, among others.